

RESEARCH

Open Access

Identification of haplotype tag single nucleotide polymorphisms within the receptor for advanced glycation end products gene and their clinical relevance in patients with major trauma

Ling Zeng^{1†}, An-qiang Zhang^{1†}, Wei Gu¹, Jian Zhou², Lian-yang Zhang², Ding-yuan Du³, Mao Zhang⁴, Hai-yan Wang¹, Jun Yan¹, Ce Yang¹ and Jian-xin Jiang^{1*}

Abstract

Introduction: The receptor for advanced glycation end products (*RAGE*) has been considered as one of the major pattern recognition receptors and plays an important role in the development of sepsis and multiple organ dysfunction in critical illnesses. Although genetic variants of the *RAGE* gene have been shown to be well associated with susceptibility to some inflammatory diseases, little is known about their clinical relevance in the development of sepsis in critical ill patients.

Methods: Four genetic variants were selected from the entire *RAGE* gene and genotyped using pyrosequencing and polymerase chain reaction-length polymorphism methods. Association studies were performed in two independent Chinese Han populations.

Results: Among the four genetic variants, only the rs1800625 polymorphism was significantly associated with sepsis morbidity rate and multiple organ dysfunction (MOD) scores in patients with major trauma both in Chongqing (n = 496) and Zhejiang (n = 232) districts, respectively. Results from *ex vivo* responsiveness of peripheral blood leukocytes indicated that the rs1800625 polymorphism was well associated with decreased production of TNF α . In addition, the rs1800625 polymorphism could significantly inhibit the promoter activities of the *RAGE* gene.

Conclusions: The rs1800625 polymorphism is a functional variant, which might be used as a relevant risk estimate for the development of sepsis and multiple organ dysfunction syndrome in patients with major trauma.

Introduction

The receptor for advanced glycation end products (*RAGE*), not only limiting to mediation of advanced glycation end products (AGEs), has been recognized as a multiligand receptor, especially playing pivotal roles in innate immune responses as a pattern-recognition receptor (PRR) in sensing both pathogen-associated molecular patterns (PAMPs) and endogenous damage-associated molecular patterns (DAMPs) [1-6]. *RAGE* could up-regulate the capacity of leukocytes to kill bacteria [2] and facilitates

host defense during bacterial infection [3,4]. Besides its anti-microbial effects, *RAGE* also acts as an endothelial adhesion receptor for leukocyte integrins and promotes leukocyte recruitment [5]. Engagement of *RAGE* by its diverse ligands, such as lipopolysaccharides, high-mobility group box 1 protein, AGEs, results in receptor-dependent signaling and amplification of pro-inflammatory responses [1]. *RAGE* is up-regulated at levels of both mRNA and protein in sepsis [6]. Administration of AGE-modified protein has the potential to activate *RAGE*/NF- κ B-mediated inflammatory reactions, causing increased mortality in experimental peritonitis [7]. In addition, the genomic deletion of *RAGE* [8,9], or inhibition of *RAGE* signaling [8,10] results in markedly decreased septic response and significantly increased survival rates in a mouse model of sepsis.

* Correspondence: hellojx@126.com

† Contributed equally

¹State Key Laboratory of Trauma, Burns and Combined Injury, Institute of Surgery Research, Daping Hospital, Third Military Medical University, Changjiang Road 10, Yuzhong District, Chongqing, 400042, China
Full list of author information is available at the end of the article

Therefore, *RAGE* has been considered to be one of the major PRRs responsible for the development of sepsis [11] and its subsequent organ dysfunction [12-14]. It might be used as a potential molecular marker and therapeutic target for sepsis [15-17].

The *RAGE* gene is located on chromosome 6p21.3 in the major histocompatibility complex (MHC) locus in the class III region [18]. Growing evidence indicates that allelic variation within the key domains of *RAGE* gene may influence the magnitude of proinflammatory response, thereby affecting susceptibility to acute and chronic inflammatory diseases [19]. A total of 97 genetic variants have been identified so far in the entire *RAGE* gene. However, only three of them (rs1800625, rs1800624 and rs2070600) have been well studied in relation to their clinical relevance. The rs1800625 is revealed in association with increased risk for diabetes [20], diabetic retinopathy [21] and colorectal cancer [22]. The rs1800624 polymorphism was shown to be associated with increased susceptibility to Crohn's disease [23], coronary artery disease [24], in-stent restenosis after coronary stent implantation [25], ischemic heart disease [26], and myocardial infarction [27]. The rs2070600 polymorphism revealed increased risk of rheumatoid arthritis [28], multiple sclerosis [29] and coronary artery disease in non-diabetics [30]. In spite of the above findings, there also have been plenty of controversial reports with respect to the clinical relevance of the above three gene polymorphisms [26,27,29,31-36]. In addition, other polymorphisms, such as 2184A/G, 2245G/A, rs17493811 and rs9469089, also have been reported in relation to diabetes [37-39]. However, little is known about the clinical relevance of the genetic variants of *RAGE* gene in relation to the development of sepsis and multiple organ dysfunction syndrome (MODS).

To comprehensively assess the clinical relevance of the common genetic variants within the entire *RAGE* gene, haplotype bins were constructed to identify haplotype tagging single nucleotide polymorphisms (SNPs) (htSNPs) within the entire *RAGE* gene and its surrounding regions. In view of that, the majority of trauma patients are young people with little history of pre-existing diseases [40]. The trauma patient cohort is appropriate to investigate the association of genetic factors with susceptibility or resistance to sepsis in critically ill patients. Four genetic variants were selected, and two independent Chinese Han populations were recruited in this study cohort. The rs1800625 polymorphism (-429T/C) was demonstrated to be clinically relevant and have functional activity.

Materials and methods

Study population and clinical evaluation

A total of 728 unrelated patients with major trauma recruited in this study were Han Chinese and from Chongqing in south-western China (n = 496) and

Zhejiang in eastern China (n = 232), respectively. The trauma patients were admitted to the Department of Trauma Surgery in the Daping Hospital and the Chongqing Emergency Medical Center between 1 January 2005 and 1 May 2011, and to the Department of Trauma and Emergency in the Second Affiliated Hospital, Zhejiang University between 1 January 2008 and 1 May 2011. They were enrolled in the study if they met the following inclusion criteria: 1) were between 18 and 65 years of age, 2) expected an Injury Severity Score (ISS) greater than 16 combined with the presence of at least one life threatening injury and at least one additional severe injury in another part of the body, and 3) had a probability of survival greater than 48 h. Patients were not eligible if they had penetrating injuries or preexisting cardiovascular, respiratory, renal, hepatic, hematologic or immunologic diseases. ISS was performed according to the abbreviated injury scale by independent evaluators [41]. Standard demographic, laboratory and clinical data were extracted from a prospectively collected database. The protocol was approved by the Ethical and Protocol Review Committee of the Third Military Medical University, and informed consent was obtained from the patients and the patients' next of kin. Patient confidentiality was preserved according to the guidelines for studies of human subjects.

The patients with major trauma were prospectively monitored after admission by physicians who did not know the genotypes. The definitions of sepsis and infection were shown in Additional file 1. Daily physiologic and laboratory data were collected during the ICU stay and clinical events were recorded thereafter, until death or hospital discharge. Multiple organ dysfunction scores were calculated as the sum of the simultaneously obtained individual organ scores on each hospital day [42]. Neurological scoring was not performed because every patient was sedated. MODS is defined as a Marshall score of 4 or more for at least two consecutive days based on the comparative studies reported by A Sauaia [43].

Tag SNP selection

The human *RAGE* gene (Accession Number: NC_000006) was pinpointed to chromosome 6, position 32148745-32152022 (data retrieved from Genbank in the website of NCBI). The *RAGE* 5' flanking region from -505 in a 5' direction has been shown to overlap with *PBX2*, a gene that has a pseudogene copy on chromosome 3, which might make any studies of polymorphisms in this duplicated region potentially fraught with error [44]. Therefore, besides all exons and introns of the *RAGE* gene, 505-bp upstream of the transcription start site and 5,000-bp downstream of the stop codon were included (8.872 kb total).

Genetic variation data for the entire *RAGE* gene and its surrounding selected regions were obtained from the healthy Chinese Han Beijing (CHB) population of HapMap. From this database, a total of 11 SNPs have been identified in the CHB population (Table 1). Ten of them were common SNPs with a minor allele frequency (MAF) more than or equal to 0.05, which were then selected for the analysis of htSNPs (Figure 1). Haplotype blocks (bins) were constructed using LDselect (Christopher S. Carlson and Deborah A. Nickerson, Seattle, Washington, USA), a software package that provides computation of linkage disequilibrium (LD) statistics and population haplotype patterns from genotype data [45]. This algorithm selects a subset of htSNPs that efficiently describe all common patterns of variants in a gene, based on two primary criteria: 1) the MAF is more than or equal to 0.05 and 2) the minimum level of association between assayed and unassayed SNPs, measured by the linkage disequilibrium statistic r^2 is more than or equal to 0.8. Given these parameters, LDSelect selects a subset of htSNPs that captures all known common genetic variants within the entire gene.

To determine the possible functionality of the htSNPs selected from the 5'-flanking region of the *RAGE* gene, on-line software was used to analyze the effect of these SNPs on potential transcription factor binding sites.

Genotyping

Blood specimens were collected in tripotassium ethylenediamine tetraacetic acid sterile tubes from trauma patients immediately after admission to avoid the effect of blood transfusion. The genomic DNA was isolated from whole blood using the Wizard genomic DNA purification kit (Promega, Madison, WI, USA) according to the manufacturer's protocol. Pyrosequencing was used for genotyping of rs1800625, rs1800624 and rs2070600 polymorphisms according to our previous reports [46]. Polymerase chain

reaction (PCR) - length polymorphism (LP) approach was used for genotyping of the 63 bp ins/del variant. The PCR primers and the annealing temperature were shown in Additional file 2, Table S1. Genotyping was performed in a blinded fashion without knowledge of the patients' clinical data, and approximately 10% of the samples were genotyped in duplicate to monitor genotyping quality.

Ex vivo tumor necrosis factor α production

A human whole-blood assay was used as in our previous method. In brief, aliquots of whole blood collected from the trauma patients immediately after admission were mixed 1:1 with Roswell Park Memorial Institute (RPMI) 1640 culture medium (Thermo Scientific, Beijing, China), and incubated with 100 ng/ml LPS (*Escherichia coli* O26: B6, Difco Laboratories, Detroit, MI, USA) in a sample mixer at 37°C for 4 h. After centrifugation, the supernatants were aspirated and aliquoted for *stoRAGE* at -80°C. Tumor necrosis factor-alpha (TNF- α) in the supernatants was assayed with a sandwich enzyme linked immunosorbent assay (ELISA), according to the manufacturer's instructions (Endogen, Woburn, MA, USA). The detection limits of the assay were 4 pg/ml.


Functionality of the rs1800625 polymorphism

The possible effect of rs1800625, which is located in the 5'-flanking region (-429T/C), on the promoter activity was investigated using a reporter gene assay system [47]. A 531-bp sequence (-504 approximately +26) of the *RAGE* gene containing T or C allele at position -429 were obtained according to the method described in Additional file 3 and were directly inserted into a promoterless pGL3-Basic vector (Promega, Madison, WI, USA) containing the firefly luciferase gene as a reporter. Human U937 were cultured in RPMI 1640 medium (Hyclone, Logan, UT, USA) containing 10% fetal calf serum, 3 mM glutamine, penicillin-streptomycin (100 U/mL for each), and 23 mM sodium bicarbonate at 37°C in a humidified 5% CO₂ air atmosphere. After incubation for 24 hours, the cultured cells were co-transfected with 0.8 μ g of the constructed vectors or pGL3-Basic original plasmid and 20 ng control Renilla luciferase reporter plasmid pRL-CMV using Lipofectmine 2000 system (Invitrogen, Carlsbad, CA, USA). At 24 hours post-transfection, the cells were treated with LPS (100 ng/mL) for 24 hours. Then luciferase activity of the transfected cells was measured using the Luciferase Assay System (Promega) following the supplier's protocol on a Luminoskan Ascent luminometer (Thermo Labsystems, Helsinki, Finland). Transfection efficiency was normalized by measuring the luciferase activity of control plasmid pRL-CMV. Luminescence experiments were performed in triplicate with each transfection. Three independent transfections were performed for each constructed vector. Results are expressed as fold increase in relative luciferase

Table 1 SNPs identified within whole *RAGE* gene

NO.	rs number	Location	Variation	MAF	Region
1	rs1800625	-429	T/C	0.122	promoter
2	rs1800624	-374	T/A	0.163	promoter
3	rs3131300	79	A/G	0.122	Intron1
4	rs2070600	570	G/A	0.289	Exon3
5	rs2269422	719	A/G	0.057	Intron3
6	rs1035798	791	C/T	0.167	Intron3
7	rs184003	1717	G/T	0.116	Intron5
8	rs3134940	2197	A/G	0.11	Intron7
9	rs2853807	2441	C/T	0.068	Intron7
10	rs2071288	2753	G/A	0.022	Intron8
11	rs8365	3610	C/G	0.114	3'-flanking

Genetic variation data for the entire *RAGE* gene was obtained from the HapMap project for 45 members of the Chinese Han Beijing (CHB) population. MAF, minor allele frequency; SNPs, single nucleotide polymorphisms



activity of the *RAGE* promoter construct vectors compared with the relative luciferase activity of pGL3-Basic.

Statistical analysis

Sample size was calculated using online Power and Sample Size Program software (William D Dupont and Walton D Plummer, Nashville, Tennessee, USA) [48]. The desired power of our study was set at 80% with a significance level of 0.05 in a two-sided test. We chose the log-additive inheritance model, which is the most suitable for polygenic diseases.

Allele frequencies for each SNP were determined by gene counting. Genotype distribution of each SNP was tested for departure from Hardy-Weinberg equilibrium (HWE) using χ^2 analyses. The extent of pair-wise linkage disequilibrium between polymorphisms was determined by the Haploview (version 4.0) software (Jeffrey C Barrett and Mark J Daly, Cambridge, MA, USA). The association between polymorphisms and supernatant TNF α was determined using one-way analysis of variance. The association between polymorphisms and MOD scores was performed using analysis of one-way ANOVA testing with age, sex ratio and injury severity to adjust for possible confounding effects. Three genetic models (dominant, recessive and allele-dose effects) were used. The association of genotypes with sepsis morbidity rate was determined by χ^2 analysis. Odds ratios with 95% confidence intervals were calculated by multiple logistic regression analyses to estimate the relative risk of sepsis. Age, sex ratio and injury severity were used as covariates of multiple logistic regression. *P*-values smaller than 0.05 after Bonferroni correction for multiple testing were considered significant. All statistical analysis was carried out using SPSS Version 13.0.

Results

Construction of haplotype bins and selection of htSNPs

There are a total of 10 SNPs with a minor allele frequency of more than or equal to 5% in the CHB population, which constructed two haplotype bins (Figure 1). Based on the analysis of tagging threshold of r^2 of SNPs in each bin, one htSNP was selected from each bin for genotyping. In combination with previous association studies [21], the rs1800625 and rs1800624 polymorphisms were selected as htSNP of the respective bins (Figure 1). The rs2070600 polymorphism, though not forming any bin with other SNPs, was still selected due to its nonsynonymous variation, showing a substitution of the conserved glycine to serine at amino acid 82 (Gly82Ser) [19]. In addition, a deletion variant (63 bp ins/del) was identified in the region of 5'-flanking region (-407 to -345). This variant, although not being included in the current public gene polymorphism database, was shown to affect the promoter activities of the *RAGE* gene [21]. As a result, this variant was also selected in this study cohort.

Overall clinical characteristics of patients with major trauma

There were two independent patient cohorts, consisting of 496 and 232 individuals, respectively. All patients survived at least 48 hours after admission and completed genotyping. Baseline data of the patients are shown in Table 2. Patients were severely injured and mostly young. Sepsis morbidity rate was 40.7% and 37.9%, respectively in the Chongqing and Zhejiang cohorts. No pathogens were identified in blood cultures in 53.0% and 50.0% of the patients in both cohorts as the causative microorganism for sepsis, although they had an identified site of infection. The common pathogens identified in this study cohort

Table 2 Overall clinical characteristics of patients with major trauma

	Chongqing (N = 496)	Zhejiang (N = 232)
Age (yrs)	40.4 ± 14.2 (18 to 65)	41.0 ± 13.1 (18 to 65)
Male/female, n	395/101	190/42
Injured body regions, n (%)		
Head, n	187 (37.7)	73 (31.5)
Thorax, n	205 (41.3)	142 (61.2)
Abdomen, n	136 (27.4)	74 (31.9)
Extremities, n	252 (50.8)	165 (71.1)
Number of regions injured, n (%)		
One, n	145 (29.2)	74(31.9)
Two, n	133 (26.8)	59 (25.4)
Three or above, n	80 (16.1)	37 (15.9)
ISS	22.0 ± 10.5	23.3 ± 8.7
≥16, <25, n (%)	301 (60.7)	131 (56.5)
≥25, n (%)	195 (39.3)	101 (43.5)
Organ dysfunction, n (%)		
One, n	132 (26.6)	76 (32.8)
Two, n	125 (25.2)	59 (25.4)
Three or above, n	72 (14.5)	35 (15.1)
Sepsis, n (%)	202 (40.7)	88 (37.9)
Source of infection, %		
Respiratory tract infection	41.6	39.8
Primary bloodstream infection	21.8	23.9
Urinary tract infection	16.3	11.4
Catheter associated infection	10.9	9.1
Wound infection	7.4	9.1
Others*	2.0	6.8
Pathogens, % (positive blood cultures)		
Gram-negative	21.0	24.6
Gram-positive	18.0	15.9
Fungi	2.2	2.2
Mixed Gram negative and positive	5.8	7.3
Negative blood cultures	53.0	50.0

were *Staphylococcus aureus*, coagulase-negative staphylococci, *Klebsiella pneumoniae*, *Acinetobacter baumannii*, *Pseudomonas aeruginosa*, *Escherichia coli*, *Enterococcus* spp. and *Enterobacter cloacae*. Gram negative infection accounted for about 21% and 24.6%, Gram positive infection for about 18% and 15.9%, and mixed infection for about 5.8% and 7.3%, respectively, in the Chongqing and Zhejiang cohorts. Median time point for sepsis occurrence in the whole study cohort was 6.0 days (interquartile range 5.0 to 9.0 days. Chongqing: median 7.0 days, interquartile range 5.0 to 8.0 days; Zhejiang: median 6.0 days, interquartile range 5.0 to 7.0 days). Organ dysfunction occurred in 72.1% and 73.2% of the patients in both cohorts, among whom 213 (42.9%) and 96 (41.4%), respectively, had two or more organ dysfunctions. Among the patients with MODS, those with sepsis accounted for 40.7% and 37.9% in Chongqing and Zhejiang populations, respectively. Among the patients with sepsis, the median time point for

MODS occurrence was shown to be 8.0 days (interquartile range 6.5 to 10.5 days) in Chongqing, and 9.0 days (interquartile range 7.0 to 11.0 days) in Zhejiang patients, respectively. With respect to the patients without sepsis, the median time point for MODS occurrence was 5.0 days (interquartile range 4.0 to 8.0 days) in Chongqing, and 5.5 days (interquartile range 3.5 to 7.5 days) in Zhejiang patients, respectively.

Allele frequencies and genotype distribution

The MAF of the rs2070600, rs1800624 and rs1800625 polymorphisms among the trauma patients were similar to those among the CHB population in the HapMap database (Table 3). The MAF of the 63 bp ins/del variant was 7.7% and 6.3% in the Chongqing and Zhejiang districts, respectively. This seems to be higher in the Chinese Han population when compared with that in Western populations, among whom the MAF of the 63 bp ins/del variant is less

Table 3 Distribution of the four variants in the RAGE gene among trauma patients

	SNPs	N	MA (%)		Genotypes, n (%)			HWE <i>P</i> -values
			Patients	Databank	wild	Heterozygous	variant	
Chongqing	63bp ins/del	496	7.7		423 (85.3)	70 (14.1)	3 (0.6)	0.96
	rs2070600	496	29.4	28.9	247 (49.8)	206 (41.5)	43 (8.7)	0.99
	rs1800624	496	14.8	16.3	364 (73.4)	117 (23.6)	15 (3.0)	0.14
	rs1800625	496	14.7	12.2	365 (73.6)	116 (23.4)	15 (3.0)	0.128
Zhejiang	63bp ins/del	232	6.3		203 (87.5)	29 (12.5)	0 (0)	0.31
	rs2070600	232	27.4	28.9	126 (54.3)	85 (36.6)	21 (9.1)	0.23
	rs1800624	232	11.6	16.3	181 (78.0)	48 (20.7)	3 (1.3)	0.93
	rs1800625	232	15.9	12.2	163 (70.3)	64 (27.6)	5 (2.2)	0.66

than 1% [21]. The genotype distribution of the four genetic variants was in agreement with the Hardy-Weinberg equilibrium ($P > 0.05$, Table 3), indicating that both allele and genotype frequencies of these variants in the population remain constant; that is, they are in equilibrium from generation to generation.

Clinical relevance of the four genetic variants in trauma patients in the Chongqing district

We first selected 496 Chinese Han patients with major trauma in the Chongqing district to investigate the clinical relevance of the four variants (63 bp ins/del, rs2070600, rs1800624 and rs1800625) of the RAGE gene. As shown in Table 4, there were no significant differences in age, gender ratio and ISS among patients stratified according to the different genotypes of each variant. Among the four genetic variants selected in this study, only the rs1800625 was shown to be significantly associated with the risk for development of sepsis and MODS in major trauma patients. The patients carrying the variant C allele revealed a significantly lower sepsis morbidity rate and MOD scores, when compared with those carrying the T allele ($P = 0.003$ for sepsis morbidity rate and $P = 0.015$ for MOD scores in case of dominant effect, $P = 0.032$ for MOD scores in case of recessive effect). Data from regression analyses further indicated that the association of this polymorphism was in significant allele-dose effect with sepsis morbidity rate (OR = 0.428, 95% CI: 0.276 to 0.886, $P = 0.026$), and MOD scores ($P = 0.045$), respectively. There were no significant differences in the sepsis morbidity rate and MOD scores among different groups when patients were stratified according to the genotypes of the other three genetic variants.

The clinical relevance of the four variants in trauma patients in the Zhejiang district

In order to confirm the biological significance of the four genetic variants selected in this study, we further investigated their clinical relevance in another Chinese Han population of trauma patients, who lived in the Zhejiang

province of eastern China. As expected, only rs1800625 was shown to be significantly associated with risk of sepsis and MODS in trauma patients in the Zhejiang district. The sepsis morbidity rates and MOD scores were significantly lower in the patients carrying the variant C allele compared with those carrying the T allele ($P = 0.016$ and $P = 0.042$ for sepsis morbidity rates and MOD scores in case of dominant effect, Table 4). Data from linear regression analysis revealed that the association of this polymorphism was in borderline significant allele-dose effect with MOD scores ($P = 0.048$).

Effect of rs1800625 on LPS-induced TNF- α production

As shown in Figure 2, the rs1800625 polymorphism was well associated with the LPS responsiveness of peripheral blood leukocytes. LPS-induced TNF- α production was significantly lower in patients with the variant C allele than that in those with wild T allele (CC genotype: 5423.4 ± 2059.4 pg/ml, TC genotype: 5763.1 ± 2771.8 pg/ml and TT genotype: 6146.7 ± 3978.4 pg/ml, $P = 0.017$ for dominant effect).

Effect of the rs1800625 on promoter activity

In view of the location of the rs1800625 in the 5'-flanking region of the RAGE gene, we further hypothesized that the T→C variation of this polymorphism might affect the promoter activities of the RAGE gene. Figure 3 showed that the fold increase of relative luciferase activity (RLA) was significantly lower in cells transfected with variant C allele than those transfected with wild T allele (1.36 ± 0.11 vs. 1.57 ± 0.27 , $P = 0.032$).



Discussion

It has been demonstrated that inappropriate immune inflammatory response contributes to the development of sepsis and MODS in critically ill patients [40]. Increasing evidence suggests that genetic variants, particularly single nucleotide polymorphisms (SNPs), are critical determinants for inter-individual differences in both inflammatory responses and clinical outcome [48,49]. Delineating the variation in genes and associated differences in immune

Table 4 Clinical relevance of four variants among trauma patients

	Polymorphic sites	Genotypes	N	Age (yr)	Sex (M/F)	ISS	Sepsis, n/%	MOD score
Chongqing	63 bp ins/del	ins/ins	423	40.2 ± 14.6	334/89	22.3 ± 10.5	178 (42.1)	6.4 ± 2.4
		ins/del	70	40.9 ± 11.1	59/11	20.5 ± 10.5	23 (32.9)	6.1 ± 2.8
		del/del	3	47.3 ± 18.8	2/1	24.3 ± 8.5	1 (33.3)	6.0 ± 1.7
	rs2070600	GG	247	39.5 ± 14.4	198/49	22.2 ± 11.4	100 (40.5)	6.7 ± 2.6
		GA	206	41.0 ± 14.4	161/45	21.9 ± 9.4	84 (40.8)	6.1 ± 2.3
		AA	43	42.5 ± 11.5	36/7	22.0 ± 10.4	18 (41.9)	5.7 ± 1.6
	rs1800624	TT	364	40.4 ± 14.3	291/73	22.2 ± 10.4	148 (40.7)	6.3 ± 2.4
		TA	117	40.5 ± 14.3	91/26	21.7 ± 11.0	51 (43.6)	6.5 ± 2.5
		AA	15	39.7 ± 12.0	13/2	20.2 ± 8.8	3 (20.0)	7.0 ± 2.6
	rs1800625	TT	365	40.0 ± 14.1	291/74	22.4 ± 10.5	163 (44.7)	6.9 ± 2.4
		TC	116	42.4 ± 14.4	89/27	21.3 ± 10.7	35 (30.2)	6.0 ± 2.2
		CC	15	37.3 ± 9.9	15/0	17.2 ± 9.8	4 (26.7)	5.3 ± 1.5
						a1	a2, b1, c1	
Zhejiang	63bp ins/del	ins/ins	203	41.0 ± 12.9	165/38	23.3 ± 8.6	74 (36.4)	6.9 ± 3.4
		ins/del	29	41.1 ± 14.9	25/4	22.7 ± 9.3	14 (48.3)	8.4 ± 3.0
		del/del	0	-	-	-	0 (0)	-
	rs2070600	GG	126	41.3 ± 13.4	102/24	22.7 ± 8.6	48 (38.1)	7.1 ± 3.1
		GA	85	40.7 ± 12.4	70/15	23.0 ± 8.5	35 (41.2)	6.9 ± 3.6
		AA	21	40.6 ± 14.5	18/3	27.5 ± 8.6	5 (23.8)	6.9 ± 2.8
	rs1800624	TT	181	41.0 ± 13.3	150/31	23.4 ± 8.7	70 (38.7)	7.0 ± 3.5
		TA	48	40.6 ± 13.0	38/10	22.4 ± 8.3	16 (33.3)	7.4 ± 3.2
		AA	3	44.7 ± 7.1	2/1	28.0 ± 14.1	2 (67.7)	6.7 ± 2.3
	rs1800625	TT	163	41.4 ± 13.2	138/25	23.7 ± 8.5	70 (42.9)	7.3 ± 3.3
		TC	64	40.9 ± 13.2	47/17	21.8 ± 8.6	16 (25.0)	6.9 ± 3.2
		CC	5	37.7 ± 15.7	4/1	24.3 ± 12.0	2 (40.0)	6.3 ± 2.5
						a3	a4, c2	

A, dominant effect (variant homozygotes + heterozygotes vs. wild homozygotes) as analyzed by ANOVA, ^{a1}*P* = 0.003, ^{a2}*P* = 0.015, ^{a3}*P* = 0.016, ^{a4}*P* = 0.042; b, recessive effect (variant homozygotes vs. heterozygotes + wild homozygotes); as analyzed by ANOVA, ^{b1}*P* = 0.032; c, Allele Dose Effect as analyzed by linear regression, ^{c1}*P* = 0.045, ^{c2}*P* = 0.048.



inflammatory response might contribute to the development of new genetically tailored diagnostic and therapeutic interventions that will improve outcome in critically ill patients. *RAGE*, a member of the immunoglobulin superfamily of cell surface molecules, was initially identified and characterized as a cellular interaction site for AGEs [6]. Growing evidence has indicated that *RAGE* is an important PRR, involved in amplification of pro-inflammatory response and antimicrobial host defense [7]. The present study, to our knowledge for the first time, investigated the potential clinical relevance of the genetic variants identified within the entire *RAGE* gene in the Han Chinese population. Three SNPs (rs1800625, rs1800624 and rs2070600) are selected from 10 SNPs with a minor allele frequency of more than or equal to 5% based on LD threshold and their possible functionalities. The 63 bp ins/del variant, although being rare in Western populations with an MAF of less than 1% [21] and not being included in the current public database of the Chinese Han population, is shown to be a common polymorphism in the Chinese Han population, showing 7.7% in Chongqing and 6.3% in Zhejiang populations, respectively, in our study cohorts. Although the rs2070600 polymorphism occurs in less than 5% in many populations, such as Brazilian and Finnish populations, the MAF was approximately 20% in Asia populations [50]. This is further confirmed in our study cohorts, showing an MAF of 29.4% and 27.4% in the Chongqing and Zhejiang districts. Therefore, the four genetic variants selected in this study cohort are all common gene polymorphisms in the Chinese Han population.

Case-control study is a common and convenient association study design for finding a genetic basis of disease. However, a major limitation in this approach is the potential for population stratification when inappropriate patient-control matching occurs, such as using healthy blood donors as the control group in the study. To avoid confounding association, we only selected trauma patients and prospectively followed them to determine whether those who had genetic variants had a lesser or higher risk of post-traumatic MODS and sepsis. In addition, the patients recruited in this study cohort were all Han Chinese. In the context of a biologically relevant phenotype and a racially uniform population, this might maximize the likelihood of finding a meaningful genetic association. Furthermore, two independent patient populations from different geographic regions were used in this study cohort. Our results indicate that among the four genetic variants, only the rs1800625 polymorphism reveals a strong clinical relevance, showing lower sepsis morbidity rate and MOD scores in the patients with the variant C allele both in Chongqing and Zhejiang cohorts. This is in contrast to its association with other diseases, showing increased risk of diabetes [18], diabetic

retinopathy [19] and colorectal cancer [20]. This might be because *RAGE* plays different roles in the pathogenesis of different diseases. The other three genetic variants (rs1800624, rs2070600 and 63bp ins/del), being associated with an increased risk of some inflammatory diseases [18,26-28], are not shown to be associated with risk of sepsis and MODS in patients with major trauma in the Chongqing and Zhejiang cohorts. In combination with previous reports showing that the rs1800625 polymorphism is a common allele in other ethnic populations with the minor allele frequency of more than 10% [51-53], it might be used as a relevant risk estimate for sepsis and MODS in critical ill patients.

Given the functional significance of the rs1800625 polymorphism, we further investigated the association of this SNP with LPS-induced responsiveness of peripheral leukocytes obtained from trauma patients. The whole blood samples were taken immediately after admission in an attempt to avoid the potential effects of blood transfusion and fluid resuscitation. As we expected, the rs1800625 polymorphism is significantly associated with lower responsiveness of peripheral blood leukocytes in response to LPS stimulation, showing much lower levels of TNF α in patients carrying the variant C allele. This is in accordance with the clinical association of the rs1800625 with risk of sepsis and MODS in patients with major trauma. The rs1800625 polymorphism is located in the promoter region of the *RAGE* gene and induces T \rightarrow C substitution at position -429 [54]. Bioinformatics analysis reveals that binding sites for some transcription factors (GATA-1, GATA-2 and sp1) (motif.genome.jp/) are present in close proximity to nucleotide -429 in the promoter. In order to further determine the functionality of the rs1800625 polymorphism, we investigated the effect of the rs1800625 polymorphism on the *RAGE* promoter activity using reporter gene assay system. Using the U937 cell line, we show that the fold increase of RLA is significantly lower in the cells transfected with vectors containing -429 C allele. It suggests that T \rightarrow C variation at position -429 could significantly reduce the transcriptional activity of the *RAGE* promoter. Taken together, The T \rightarrow C variation at position -429 might reduce DNA-protein interaction, and then inhibit *RAGE* gene transcription, which contributes to decreased TNF production by peripheral blood leukocytes in response to *ex vivo* LPS stimulation, leading to decreased risk of sepsis and MODS in patients with major trauma.

There are some limitations to our current study. First, the sample size of both patient groups recruited in this study was relatively small, especially in the Zhejiang cohort. The values of power for rs1800625 in the Zhejiang cohort are shown to be 51.7% and 36.2% for sepsis morbidity rate and MOD scores, respectively, at a significance

of 0.05. The too small number size of patients with the rs1800625 TC genotype ($n = 5$) and their higher incidence of sepsis (40%) in the Zhejiang cohort might explain the discrepancy in sepsis morbidity rate between the Chongqing and Zhejiang cohorts. The clinical relevance of the rs1800625 polymorphism needs to be validated in a larger population. Second, the population we studied was only Han Chinese who live in the Chongqing and Zhejiang districts. Our results may not be generalized to other populations. Third, difficulties in obtaining additional blood samples did not allow us to determine plasma sRAGE levels, or RAGE expression on peripheral blood leukocytes; therefore, the *in vivo* association between the rs1800625 polymorphism and RAGE activities needs to be confirmed. Despite the limited power of the clinical association study, our results demonstrate that the rs1800625 polymorphism might be a causal risk allele for sepsis and MODS in patients with major trauma

Conclusions

The present study investigated the clinical relevance of the genetic variations within the entire RAGE gene by means of construction of haplotype bins in patients with major trauma. We demonstrate that rs1800625 polymorphism is shown to affect TNF α production, and might be used as a relevant risk estimate for sepsis and MODS in trauma patients. In addition, the rs1800625 polymorphism could significantly enhance the promoter activities of the RAGE gene.

Key messages

- Among the four tagSNPs of RAGE, only rs1800625 reveals a strong clinical relevance, showing lower sepsis morbidity rate and MOD scores in the patients with the variant C allele in both the Chongqing and Zhejiang cohorts.
- The rs1800625 polymorphism is significantly associated with lower responsiveness of peripheral blood leukocytes in response to LPS stimulation, showing much lower levels of TNF α in patients carrying the variant C allele.
- The rs1800625 polymorphism could significantly enhance the promoter activities of the RAGE gene.

Additional material

Additional file 1: The definition of sepsis and infection. We evaluated sepsis and infection of major trauma patients' according to these criteria.

Additional file 2: Table S1. Primers of the four variants of the RAGE gene and their PCR conditions. The PCR primers, sequencing primers and the annealing temperatures of the four variants of the RAGE gene were shown in Table S1.

Additional file 3: The methods of plasmid construction. The possible effect of -429T/C on the promoter activity was investigated using a

reporter gene assay system. Two plasmids which contained the -429T promoter and -429C promoter were constructed.

Abbreviations

AGEs, advanced glycation end products; CHB, Chinese Han Beijing; DAMPs, damage-associated molecular patterns; DNA, deoxyribonucleic acid; ELISA, enzyme-linked immunosorbent assay; htSNPs, haplotype tagging single nucleotide polymorphisms; HWE, Hardy-Weinberg equilibrium; ISS, Injury Severity Score; LD, linkage disequilibrium; LP, length polymorphism; LPS, lipopolysaccharide; MAF, minor allele frequency; MHC, major histocompatibility complex; MODS, multiple organ dysfunction syndrome; OR, odds ratios; PAMPs, pathogen-associated molecular patterns; PCR, polymerase chain reaction; PRR, pattern-recognition receptor; RAGE, receptor for advanced glycation end products; RLA, relative luciferase activity; RPMI, Roswell Park Memorial Institute; SNPs, single nucleotide polymorphisms; TNF α , tumor necrosis factor alpha

Acknowledgements

This work is supported by National Key Technology R&D Programme (2012BAI11B00).

Author details

¹State Key Laboratory of Trauma, Burns and Combined Injury, Institute of Surgery Research, Daping Hospital, Third Military Medical University, Changjiang Road 10, Yuzhong District, Chongqing, 400042, China. ²Department of Traumatic Surgery, Daping Hospital, Third Military Medical University, Changjiang Road 10, Yuzhong District, Chongqing, 400042, China. ³Chongqing Emergency Medical Center, Jiankang Road, Yuzhong District, Chongqing, 400042, China. ⁴Department of Emergency Medical Center, the Second Affiliated Hospital, Zhejiang University, Jiefang Road 88, Zhejiang, 310009, China.

Authors' contributions

LZ and A-QZ were the main researchers for this study and co-contributed to the writing of this manuscript. WG, JZ, L-YZ, D-YD, MZ, JY and CY were involved in the collecting of blood samples and other clinical data. H-YW did the technical work. J-XJ planned the study, wrote the protocol and was involved in the genetic and clinical aspects of data analyses and revised the manuscript. All authors read and approved the final manuscript.

Competing interests

The authors declare that they have no competing interests.

Received: 3 April 2012 Revised: 13 June 2012 Accepted: 24 July 2012
Published: 24 July 2012

References

1. van Zoelen MA, Achouiti A, van der Poll T: RAGE during infectious diseases. *Front Biosci* 2011, **3**:1119-1132.
2. Tadie JM, Bae HB, Banerjee S, Zmijewski JW, Abraham E: Differential activation of RAGE by HMGB1 modulates neutrophil associated NADPH oxidase activity and bacterial killing. *Am J Physiol Cell Physiol* 2011, **302**:249-256.
3. van Zoelen MA, Schmidt AM, Florquin S, Meijers JC, de Beer R, de Vos AF, Nawroth PP, Bierhaus A, van der Poll T: Receptor for advanced glycation end products facilitates host defense during *Escherichia coli*-induced abdominal sepsis in mice. *J Infect Dis* 2009, **200**:765-773.
4. Clynes R, Herold K, Schmidt AM: RAGE: exacting a toll on the host in response to polymicrobial sepsis and *Listeria monocytogenes*. *Crit Care* 2007, **11**:183.
5. Frommhold D, Kamphues A, Hepper I, Pruenster M, Lukic IK, Socher I, Zablotskaya V, Buschmann K, Lange-Sperandio B, Schymeinsky J, Ryschich E, Poeschl J, Kupatt C, Nawroth PP, Moser M, Walzog B, Bierhaus A, Sperandio M: RAGE and ICAM-1 cooperate in mediating leukocyte recruitment during acute inflammation *in vivo*. *Blood* 2010, **116**:841-849.
6. Hu YM, Pai MH, Yeh CL, Hou YC, Yeh SL: Glutamine administration ameliorates sepsis-induced kidney injury by downregulating the high-mobility group box protein-1-mediated pathway in mice. *Am J Physiol Renal Physiol* 2012, **302**:F150-F158.

7. Humpert PM, Lukic IK, Thorpe SR, Hofer S, Awad EM, Andrassy M, Deemer EK, Kasper M, Schleicher E, Schwaninger M, Weigand MA, Nawroth PP, Bierhaus A: **AGE-modified albumin containing infusion solutions boosts septicaemia and inflammation in experimental peritonitis.** *J Leukoc Biol* 2009, **86**:589-597.
8. Lutterloh EC, Opal SM, Pittman DD, Keith JC Jr, Tan XY, Clancy BM, Palmer H, Milarski K, Sun Y, Palardy JE, Parejo NA, Kessimian N: **Inhibition of RAGE products increases survival in experimental models of severe sepsis and systemic infection.** *Crit Care* 2007, **11**:R112.
9. Liliensiek B, Weigand MA, Beirhaus A, Nicklas W, Kasper M, Hofer S, Plachky J, Gröne HJ, Kurschus FC, Schmidt AM, Yan SD, Martin E, Schleicher E, Stern DM, Hämmerling GJ, Nawroth PP, Arnold B: **Receptor for advanced glycation end products (RAGE) regulates sepsis but not the adaptive immune response.** *J Clin Invest* 2004, **113**:1641-1650.
10. Christaki E, Opal SM, Keith JC Jr, Kessimian N, Palardy JE, Parejo NA, Tan XY, Piche-Nicholas N, Tchistiakova L, Vlasuk GP, Shields KM, Feldman JL, Lavallie ER, Arai M, Mounts W, Pittman DD: **A monoclonal antibody against RAGE alters gene expression and is protective in experimental models of sepsis and pneumococcal pneumonia.** *Shock* 2011, **35**:492-498.
11. Yamamoto Y, Harashima A, Saito H, Tsuneyama K, Munesue S, Motoyoshi S, Han D, Watanabe T, Asano M, Takasawa S, Okamoto H, Shimura S, Karasawa T, Yonekura H, Yamamoto H: **Septic shock is associated with receptor for advanced glycation end products ligation of LPS.** *J Immunol* 2011, **186**:3248-3257.
12. Calfee CS, Ware LB, Eisner MD, Parsons PE, Thompson BT, Wickersham N, Matthay MA, NHLBI ARDS Network: **Plasma receptor for advanced glycation end products and clinical outcomes in acute lung injury.** *Thorax* 2008, **63**:1083-1089.
13. Boyd JH, Kan B, Roberts H, Wang Y, Walley KR: **S100A8 and S100A9 mediate endotoxin-induced cardiomyocyte dysfunction via the receptor for advanced glycation end products.** *Circ Res* 2008, **102**:1239-1346.
14. Sadik NA, Mohamed WA, Ahmed MI: **The association of receptor of advanced glycated end products and inflammatory mediators contributes to endothelial dysfunction in a prospective study of acute kidney injury patients with sepsis.** *Mol Cell Biochem* 2012, **359**:73-81.
15. Bopp C, Hofer S, Weitz J: **sRAGE is elevated in septic patients and associated with patients outcome.** *J Surg Res* 2008, **147**:79-83.
16. Nakamura T, Sato E, Fujiwara N, Kawagoe Y, Suzuki T, Ueda Y, Yamada S, Shoji H, Takeuchi M, Ueda S, Matsui T, Adachi H, Okuda S, Yamagishi S: **Circulating levels of advanced glycation end products (AGE) and interleukin-6 (IL-6) are independent determinants of serum asymmetric dimethylarginine (ADMA) levels in patients with septic shock.** *Pharmacol Res* 2009, **60**:515-518.
17. Creagh-Brown BC, Quinlan GJ, Evans TW, Burke-Gaffney A: **The RAGE axis in systemic inflammation, acute lung injury and myocardial dysfunction: an important therapeutic target?** *Intens Care Med* 2010, **36**:1644-1656.
18. Hudson BI, Stickland MH, Grant PJ, Futers TS: **Characterization of allelic and nucleotide variation between the RAGE gene on chromosome 6 and a homologous pseudogene sequence to its 5'-regulatory region on chromosome 3.** *Diabetes* 2001, **50**:2646-2651.
19. Kim OY, Jo SH, Jang Y, Chae IS, Kim JY, Hyun YJ, Lee JH: **G allele at RAGE SNP82 is associated with proinflammatory markers in obese subjects.** *Nutr Res* 2009, **29**:106-113.
20. Laki J, Kiszal P, Vatay A: **The HLA 8.1 ancestral haplotype is strongly linked to the C allele of -429T>C promoter polymorphism of receptor of the advanced glycation endproduct (RAGE) gene. Haplotype-independent association of the -429C allele with high hemoglobinA1C levels in diabetic patients.** *Mol Immunol* 2007, **44**:648-655.
21. Hudson BI, Stickland MH, Futers TS, Grant PJ: **Effects of novel polymorphisms in the RAGE gene on transcriptional regulation and their association with diabetic retinopathy.** *Diabetes* 2001, **50**:1505-1511.
22. Tóth EK, Kocsis J, Madaras B, Bíró A, Pocsai Z, Fust G, Blaskó B, Karádi I, Adány R, Laki J: **The 8.1 ancestral MHC haplotype is strongly associated with colorectal cancer risk.** *Int J Cancer* 2007, **121**:1744-1748.
23. Dabritz J, Friedrichs F, Weinhage T, Hampe J, Kucharzik T, Lügering A, Broeckel U, Schreiber S, Spiekler T, Stoll M, Foell D: **The functional -374T/A polymorphism of the receptor for advanced glycation end products may modulate Crohn's disease.** *Am J Physiol Gastrointest Liver Physiol* 2011, **300**:G823-G832.
24. Falcone C, Geroldi D, Buzzi MP, Emanuele E, Yilmaz Y, Fontana JM, Vignali L, Boiocchi C, Sbarsi I, Cuccia M: **The -374T/A RAGE polymorphism protects against future cardiac events in nondiabetic patients with coronary artery disease.** *Arch Med Res* 2008, **39**:320-325.
25. Falcone C, Emanuele E, Buzzi MP, Ballerini L, Repetto A, Canosi U, Mazzucchelli I, Schirinzi S, Sbarsi I, Boiocchi C, Cuccia M: **The -374T/A variant of the RAGE gene promoter is associated with clinical restenosis after coronary stent placement.** *Int J Immunopathol Pharmacol* 2007, **20**:771-777.
26. dos Santos KG, Canani LH, Gross JL, Tschiedel B, Pires Souto KE, Roisenberg I: **The -374A allele of the receptor for advanced glycation end products gene is associated with a decreased risk of ischemic heart disease in African-Brazilians with type 2 diabetes.** *Mol Genet Metab* 2005, **85**:149-156.
27. Pettersson-Fernholm K, Forsblom C, Hudson BI, Perola M, Grant PJ, Groop PH: **The functional -374 T/A RAGE gene polymorphism is associated with proteinuria and cardiovascular disease in type 1 diabetic patients.** *Diabetes* 2003, **52**:891-894.
28. Hofmann MA, Drury S, Hudson BI, Gleason MR, Qu W, Lu Y, Lalla E, Chitnis S, Monteiro J, Stickland MH, Bucciarelli LG, Moser B, Moxley G, Itescu S, Grant PJ, Gregersen PK, Stern DM, Schmidt AM: **RAGE and arthritis: the G82S polymorphism amplifies the inflammatory response.** *Genes Immun* 2002, **3**:123-135.
29. Li K, Zhao B, Dai D, Yao S, Liang W, Yao L, Yang Z: **A functional p.82G>S polymorphism in the RAGE gene is associated with multiple sclerosis in the Chinese population.** *Mult Scler* 2011, **17**:914-921.
30. Kucukhuseyin O, Yilmaz-Aydogan H, Isbir CS, Isbir T: **Is there any association between GLY82 ser polymorphism of RAGE gene and Turkish diabetic and non diabetic patients with coronary artery disease?** *Mol Biol Rep* 2012, **39**:4423-4428.
31. Ng ZX, Kuppusamy UR, Tajunisah I, Fong KC, Chua KH: **Association analysis of -429T/C and -374T/A polymorphisms of receptor of advanced glycation end products (RAGE) gene in Malaysian with type 2 diabetic retinopathy.** *Diabetes Res Clin Pract* 2012, **95**:372-377.
32. Kalousova M, Brabcová I, Germanová A, Jáchymová M, Matl I, Mestek O, Bandúr S, Zima T, Viklický O: **RAGE polymorphisms, renal function and histological finding at 12 months after renal transplantation.** *Clin Biochem* 2009, **42**:347-352.
33. Globocnik PM, Steblovník K, Peterlin B, Pitrovic D: **The - 429 T/C and - 374 T/A gene polymorphisms of the receptor of advanced glycation end products gene are not risk factors for diabetic retinopathy in Caucasians with type 2 diabetes.** *Klin Monbl Augenheilkd* 2003, **220**:873-876.
34. Ramprasad S, Radha V, Mathias RA, Majumder PP, Rao MR, Rema M: **RAGE gene promoter polymorphisms and diabetic retinopathy in a clinic-based population from South India.** *Eye (Lond)* 2007, **21**:395-401.
35. Lu L, Jin Pu L, Chen QJ, Wang L, Peng W, Yan X, Zhang Q, Yan Zhang R, Gong PH, Qiu JP, Shen WF: **Increased glycated albumin and decreased esRAGE concentrations are associated with in-stent restenosis in Chinese diabetic patients.** *Clin Chim Acta* 2008, **396**:33-37.
36. Prevost G, Fajardy I, Fontaine P, Danze PM, Besmond C: **Human RAGE GLY82SER dimorphism and HLA class II DRB1-DQA1-DQB1 haplotypes in type 1 diabetes.** *Eur J Immunogenet* 1999, **26**:343-348.
37. Ng ZX, Kuppusamy UR, Tajunisah I, Fong KC, Koay AC, Chua KH: **2245G/A polymorphism of the receptor for advanced glycation end-products (RAGE) gene is associated with diabetic retinopathy in the Malaysian population.** *Br J Ophthalmol* 2012, **96**:289-292.
38. Forbes JM, Soderlund J, Yap FY, Knip M, Andrikopoulos S, Ilonen J, Simell O, Veijola R, Sourris KC, Coughlan MT, Forsblom C, Slattery R, Grey ST, Wessman M, Yamamoto H, Bierhaus A, Cooper ME, Groop PH: **Receptor for advanced glycation end-products (RAGE) provides a link between genetic susceptibility and environmental factors in type 1 diabetes.** *Diabetologia* 2011, **54**:1032-1042.
39. Kanková K, Stejskalová A, Pácal L, Tschoplová S, Hertlová M, Krusová D, Izakovicová-Hollá L, Beránek M, Vasků A, Barral S, Ott J: **Genetic risk factors for diabetic nephropathy on chromosomes 6p and 7q identified by the set-association approach.** *Diabetologia* 2007, **50**:990-999.
40. Jiang JX, Li L: **The development and perspective of wound and trauma in wound.** *Med J Chin PLA* 2010, **35**:781-784.
41. **The Abbreviated Injury Scale: 2005 revision. Association for the Advancement of Automotive Medicine.** 2005 [http://www.AAAM.org].
42. Marshall JC, Cook DJ, Christou NV, Bernard GR, Sprung CL, Sibbald WJ: **Multiple organ dysfunction score: a reliable descriptor of a complex clinical outcome.** *Crit Care Med* 1995, **23**:1638-1652.

43. Sauaia A, Moore EE, Johnson JL, Ciesla DJ, Biffl WL, Banerjee A: **Validation of Postinjury Multiple Organ Failure scores.** *Shock* 2009, **31**:438-447.
44. Hudson BJ, Stickland MH, Grant PJ, Futers TS: **Characterization of allelic and nucleotide variation between the RAGE gene on chromosome 6 and a homologous pseudogene sequence to its 5' regulatory region on chromosome 3: implications for polymorphic studies in diabetes.** *Diabetes* 2001, **50**:2646-2651.
45. Carlson CS, Eberle MA, Rieder MJ, Yi Q, Kruglyak L, Nickerson DA: **Selecting a maximally informative set of single-nucleotide polymorphisms for association analyses using linkage disequilibrium.** *Am J Hum Genet* 2004, **74**:106-120.
46. Zeng L, Gu W, Zhang AQ, Zhang M, Zhang LY, Du DY, Huang SN, Jiang JX: **A functional variant of lipopolysaccharide binding protein predisposes to sepsis and organ dysfunction in patients with major trauma.** *Ann Surg* 2012, **255**:147-157.
47. Gu W, Shan YA, Zhou J, Jiang DP, Zhang LY, Du DY, Wang ZG, Jiang JX: **Functional significance of gene polymorphisms in the promoter of myeloid differentiation-2.** *Ann Surg* 2007, **46**:151-158.
48. Dupont WD, Plummer WD Jr: **PS: Power and Sample Size Calculation version 3.0.** 2009 [<http://biostat.mc.vanderbilt.edu/twiki/bin/view/Main/PowerSampleSize>].
49. Zeng L, Gu W, Chen KH, Jiang DP, Zhang LY, Du DY, Hu P, Liu Q, Huang SN, Jiang JX: **Clinical relevance of the interleukin 10 promoter polymorphisms in Chinese Han patients with major trauma: genetic association studies.** *Crit Care* 2009, **13**:1-8.
50. Liu LM, Xiang KS: **RAGE Gly82Ser polymorphism in diabetic microangiopathy.** *Diabetes Care* 1999, **22**:645-654.
51. Prasad P, Tiwari AK, Kumar KM, Ammini AC, Gupta A, Gupta R, Thelma BK: **Association analysis of ADPRT1, AKR1B1, RAGE, GFPT2 and PAI-1 gene polymorphisms with chronic renal insufficiency among Asian Indians with type-2 diabetes.** *BMC Medical Genetics* 2010, **11**:52.
52. Santos IC, Daga DR, Frigeri HR, Réa RR, Almeida AC, Souza EM, Pedrosa FO, Fadel-Picheth CM, Picheth G: **The functional polymorphisms -429T>C and -374T>A of the RAGE gene promoter are not associated with gestational diabetes in Euro-Brazilians.** *Genet Mol Res* 2010, **9**:1130-1135.
53. Kirbis J, Milutinović A, Steblovnik K, Teran N, Terzić R, Zorc M: **The -429 T/C and -374 T/A gene polymorphisms of the receptor of advanced glycation end products gene (RAGE) are not risk factors for coronary artery disease in Slovene population with type 2 diabetes.** *Coll Antropol* 2004, **28**:611-616.
54. Li J, Schmidt AM: **Characterization and functional analysis of the promoter of RAGE, the receptor for advanced glycation end products.** *J Biol Chem* 1997, **272**:16498-16506.

doi:10.1186/cc11436

Cite this article as: Zeng *et al.*: Identification of haplotype tag single nucleotide polymorphisms within the receptor for advanced glycation end products gene and their clinical relevance in patients with major trauma. *Critical Care* 2012 **16**:R131.

Submit your next manuscript to BioMed Central and take full advantage of:

- Convenient online submission
- Thorough peer review
- No space constraints or color figure charges
- Immediate publication on acceptance
- Inclusion in PubMed, CAS, Scopus and Google Scholar
- Research which is freely available for redistribution

Submit your manuscript at
www.biomedcentral.com/submit

